GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Shineway Pharmaceutical Group Ltd (HKSE:02877) » Definitions » Revenue

China Shineway Pharmaceutical Group (HKSE:02877) Revenue : HK$4,563 Mil (TTM As of Jun. 2024)


View and export this data going back to 2004. Start your Free Trial

What is China Shineway Pharmaceutical Group Revenue?

China Shineway Pharmaceutical Group's revenue for the six months ended in Jun. 2024 was HK$2,246 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2024 was HK$4,563 Mil. China Shineway Pharmaceutical Group's Revenue per Share for the six months ended in Jun. 2024 was HK$2.97. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was HK$6.04.

Warning Sign:

China Shineway Pharmaceutical Group Ltd revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of China Shineway Pharmaceutical Group was -8.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was 16.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was 13.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was 7.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, China Shineway Pharmaceutical Group's highest 3-Year average Revenue per Share Growth Rate was 30.50% per year. The lowest was -7.10% per year. And the median was 12.65% per year.


China Shineway Pharmaceutical Group Revenue Historical Data

The historical data trend for China Shineway Pharmaceutical Group's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Shineway Pharmaceutical Group Revenue Chart

China Shineway Pharmaceutical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,011.10 3,148.16 3,947.13 4,411.73 4,940.09

China Shineway Pharmaceutical Group Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,127.77 2,384.68 2,623.63 2,316.47 2,246.42

Competitive Comparison of China Shineway Pharmaceutical Group's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, China Shineway Pharmaceutical Group's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Shineway Pharmaceutical Group's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Shineway Pharmaceutical Group's Revenue distribution charts can be found below:

* The bar in red indicates where China Shineway Pharmaceutical Group's Revenue falls into.



China Shineway Pharmaceutical Group Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$4,563 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China Shineway Pharmaceutical Group  (HKSE:02877) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


China Shineway Pharmaceutical Group Revenue Related Terms

Thank you for viewing the detailed overview of China Shineway Pharmaceutical Group's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


China Shineway Pharmaceutical Group Business Description

Traded in Other Exchanges
Address
Luan Cheng, Hebei Province, Shijiazhuang, CHN
China Shineway Pharmaceutical Group Ltd is an investment holding company in the People's Republic of China. It is engaged in the research, development, manufacturing, and trading of modern Chinese medicines. The company's products comprise injection, soft capsule, granule, and others of which injection generates maximum revenue to the company.
Executives
Bh Corporate Services Ltd 2301 Trustee
Bodnar-horvath Kwai Yung Helen 2202 Interest of your spouse
Bodnar-horvath Nicholas Eugene Francis 2201 Interest of corporation controlled by you
Forway Investment Limited 2101 Beneficial owner
Li Zhenjiang 2307 Founder of a discretionary trust who can infl

China Shineway Pharmaceutical Group Headlines

No Headlines